Cardior Pharmaceuticals

Cardior Pharmaceuticals company information, Employees & Contact Information

Updated June 2026

Quick answer

Cardior Pharmaceuticals is a Pharmaceutical Manufacturing company and founded in 2016. It has approximately 20 employees on record. Contact data was last refreshed in June 2026. Find Cardior Pharmaceuticals's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide. As of May 2, 2024 Cardior Pharmaceuticals GmbH is a wholly owned subsidiary of Novo Nordisk Region Europe A/S.

Company Details

Employees
20
Founded
2016
Address
Feodor-Lynen-Str. 15, Hanover,lower Saxony 30625,germany
Phone
+49 (0)511-33 85 99 30
Email
in****@****dior.de
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Hanover, Lower Saxony
Looking for a particular Cardior Pharmaceuticals employee's phone or email?

Cardior Pharmaceuticals Questions

News

Novo Nordisk to acquire Cardior Pharmaceuticals - Max-Planck-Gesellschaft zur Förderung der Wissenschaften

Novo Nordisk to acquire Cardior Pharmaceuticals Max-Planck-Gesellschaft zur Förderung der Wissenschaften

Novo Nordisk strikes deal worth up to $1.1 bln to expand cardio business - Reuters

Novo Nordisk strikes deal worth up to $1.1 bln to expand cardio business Reuters

Novo shells out $1.1bn to buy Cardior to expand cardiovascular pipeline - Pharmaceutical Technology

Novo shells out $1.1bn to buy Cardior to expand cardiovascular pipeline Pharmaceutical Technology

Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion - statnews.com

Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion statnews.com

‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field - Pharma Voice

‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field Pharma Voice

Latham & Watkins Advises Novo Nordisk on Acquisition of Cardior Pharmaceuticals - Latham & Watkins LLP

Latham & Watkins Advises Novo Nordisk on Acquisition of Cardior Pharmaceuticals Latham & Watkins LLP

Novo Nordisk Agrees to Buy Cardior Pharma for Up to €1 Billion - Bloomberg.com

Novo Nordisk Agrees to Buy Cardior Pharma for Up to €1 Billion Bloomberg.com

Novo Nordisk Acquires Cardior Pharmaceuticals for $1.112B in Effort to Bolster Cardiovascular Disease Pipeline - Pharmaceutical Executive

Novo Nordisk Acquires Cardior Pharmaceuticals for $1.112B in Effort to Bolster Cardiovascular Disease Pipeline Pharmaceutical Executive

Novo Nordisk Boosts Cardiovascular Pipeline With $1.1 Billion Purchase of Cardior Pharmaceuticals - The Wall Street Journal

Novo Nordisk Boosts Cardiovascular Pipeline With $1.1 Billion Purchase of Cardior Pharmaceuticals The Wall Street Journal

Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF‐REVERT trial - Bauersachs - 2024 - European Journal of Heart Failure - Wiley Online Library

Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF‐REVERT trial - Bauersachs - 2024 - European Journal of Heart Failure Wiley Online Library

Novo Nordisk to buy Cardior Pharmaceuticals - European Pharmaceutical Review

Novo Nordisk to buy Cardior Pharmaceuticals European Pharmaceutical Review

Novo snatches heart disease biotech Cardior Pharmaceuticals for $1.1B - Medical Marketing and Media

Novo snatches heart disease biotech Cardior Pharmaceuticals for $1.1B Medical Marketing and Media

Novo Nordisk inks $1B Cardior buyout to pump up heart failure plans - Fierce Biotech

Novo Nordisk inks $1B Cardior buyout to pump up heart failure plans Fierce Biotech

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease - GlobeNewswire

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease GlobeNewswire

Novo Nordisk Buys Heart Disease Drug Maker Cardior in $1.11 Billion Deal - Investopedia

Novo Nordisk Buys Heart Disease Drug Maker Cardior in $1.11 Billion Deal Investopedia

Novo Nordisk to Acquire Cardior for Up to $1.1B, Boosting Cardiovascular Pipeline - Genetic Engineering and Biotechnology News

Novo Nordisk to Acquire Cardior for Up to $1.1B, Boosting Cardiovascular Pipeline Genetic Engineering and Biotechnology News

Novo Nordisk to acquire Cardior Pharmaceuticals - European Biotechnology Magazine

Novo Nordisk to acquire Cardior Pharmaceuticals European Biotechnology Magazine

Novo to acquire heart failure drug in $1B deal for Cardior - BioPharma Dive

Novo to acquire heart failure drug in $1B deal for Cardior BioPharma Dive

German watchdog approves Novo's acquisition of Cardior Pharmaceuticals - Reuters

German watchdog approves Novo's acquisition of Cardior Pharmaceuticals Reuters

Bristol-backed Cardior gets $75M to run midphase antisense heart failure trial - Fierce Biotech

Bristol-backed Cardior gets $75M to run midphase antisense heart failure trial Fierce Biotech

Novo Nordisk Expands Cardio Reach by Buying Heart Drugs Biotech Cardior - MedCity News

Novo Nordisk Expands Cardio Reach by Buying Heart Drugs Biotech Cardior MedCity News

Novo Nordisk to acquire RNA specialist Cardior - Chemical & Engineering News

Novo Nordisk to acquire RNA specialist Cardior Chemical & Engineering News

Novo Nordisk Acquiring Cardior Pharmaceuticals For Up To €1.025 Billion - Pulse 2.0

Novo Nordisk Acquiring Cardior Pharmaceuticals For Up To €1.025 Billion Pulse 2.0

Novo Nordisk to acquire Germany's Cardior Pharmaceuticals for EUR 1 billion - medwatch.com

Novo Nordisk to acquire Germany's Cardior Pharmaceuticals for EUR 1 billion medwatch.com

Novo Nordisk to acquire cardiovascular disease specialist Cardior in deal worth over €1bn - PMLiVE

Novo Nordisk to acquire cardiovascular disease specialist Cardior in deal worth over €1bn PMLiVE

Cardior Pharmaceuticals’ Heart Failure Drug Shows Curative Potential - Labiotech.eu

Cardior Pharmaceuticals’ Heart Failure Drug Shows Curative Potential Labiotech.eu

Novo Nordisk $1.1bn Heart Disease Deal: What We Know About Cardior Pharmaceuticals Drug CDR132L - CCN.com

Novo Nordisk $1.1bn Heart Disease Deal: What We Know About Cardior Pharmaceuticals Drug CDR132L CCN.com

‘Germany has enormous potential in terms of basic research’ - VC Magazin

‘Germany has enormous potential in terms of basic research’ VC Magazin

Top Cardior Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant